1
|
Bania A, Adamou A, Saloustros E. Racial and Ethnic Disparities in European Breast Cancer Clinical Trials. Cancers (Basel) 2024; 16:1726. [PMID: 38730678 PMCID: PMC11082959 DOI: 10.3390/cancers16091726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2024] [Revised: 04/26/2024] [Accepted: 04/27/2024] [Indexed: 05/13/2024] Open
Abstract
Breast cancer is the most prevalent female cancer worldwide with known correlations between the race and tumor characteristics of the patients and prognosis. International and US-based studies, however, have reported a disproportionate representation of Black and Hispanic patients in clinical trials. This is the first study assessing race and ethnicity reporting trends and inclusion in European breast cancer trials. The PubMed and ClinicalTrials.gov databases were systematically searched for trials on breast cancer treatment conducted exclusively in Europe between 2010 and 2022. Of the 97 identified trials, race was reported in 10.31%. Multinational participation, but not the study size or trial phase, was significantly associated with higher race reporting trends. These 10 trials featured a White-predominant population, with 1.08% Asian and 0.88% Black patients included. The acquisition of the race and ethnicity data of patients in European trials is lower compared to the U.S. or worldwide studies and does not permit extensive analysis of minority participation. In a limited analysis, the low rates of minority participation are concerning, based on population-based data on minorities in select European countries. These observations should encourage race reporting practices in European breast cancer trials and adequate minority participation to support the generalizability of the results of the studies and promote healthcare equity.
Collapse
Affiliation(s)
- Angelina Bania
- Faculty of Medicine, School of Health Sciences, University of Patras, 26504 Patras, Greece;
| | - Antonis Adamou
- Institute of Diagnostic and Interventional Neuroradiology, Hannover Medical School, 30625 Hannover, Germany;
| | - Emmanouil Saloustros
- Division of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece
| |
Collapse
|
2
|
Veyrier CA, Roucoux G, Baumann-Coblentz L, Massol J, Karp JC, Wagner JP, Chassany O, Duracinsky M. Homeopathy as Praxis: Integration of Homeopathy as Supportive Care into Daily Life in Early Breast Cancer Patients. Integr Cancer Ther 2024; 23:15347354241233302. [PMID: 38721830 PMCID: PMC11084993 DOI: 10.1177/15347354241233302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Revised: 01/08/2024] [Accepted: 02/01/2024] [Indexed: 05/12/2024] Open
Abstract
INTRODUCTION Homeopathy is one of most widely used non-conventional supportive care methods used by women with breast cancer. This article aims to describe the routines and practices related to homeopathy as supportive care used by women with non-metastatic breast cancer in France. METHODS This qualitative study used Grounded Theory. Participants were women with early breast cancer and healthcare professionals (General Practitioner homeopaths & oncologists). Inclusion depended on specific criteria and the aim of theoretical sampling until data saturation. Data were collected through individual semi-structured interviews and focus groups following evolving topic guides. Transcribed interviews underwent in-depth thematic analysis. Inclusion, interviewing, transcription and coding occurred iteratively. Data was reported according to COREQ guidelines. RESULTS The therapeutic agency of homeopathy was distributed to different actors and ritualized material activities highly involving the patient. The choice of remedy was mostly delegated by patients to General Practitioner homeopaths (GPH) during consultations. Individualization, that is to say adaptation to the patient, differed from other modes of access to homeopathy (self-medication and oncologists). Self-medication was mostly limited to known products in a limited time frame. However, we identified a supported self-medication using trusted homeopathic protocols. Following homeopathic prescriptions involves a high level of commitment on behalf of the patient and follows different rules for homeopathy intake. This knowledge was either acquired earlier for users or discovered along breast cancer treatment for non-users. Taking homeopathy involved small daily actions for intake of different products at different times of the day. New users used strategies to ease the integration of homeopathy into their daily life. The stance toward such rules differed among patients. Some followed rules to optimize their effects while others simplified the rules and took those rituals as part of homeopathy benefits. CONCLUSION Homeopathy as supportive care in breast cancer is distributed toward different actors and ritualized activities. Homeopathy is a supported practice where GPH played a role in the prescription. Health Literacy in homeopathy played a role to ease its integration into daily life and identify the potential benefits. The high involvement of patients in their homeopathic treatment is a form of treatment reappropriation and empowerment.
Collapse
Affiliation(s)
- Clair-Antoine Veyrier
- URC ECO, Hotel-Dieu Hospital, AP-HP, Paris, France
- ECEVE UMR 1123, Inserm & Paris Cité University, Paris, France
| | - Guillaume Roucoux
- URC ECO, Hotel-Dieu Hospital, AP-HP, Paris, France
- ECEVE UMR 1123, Inserm & Paris Cité University, Paris, France
| | | | - Jacques Massol
- REMEDE Consulting & Axial, Boulogne-Billancourt, Paris, France
| | | | | | - Olivier Chassany
- URC ECO, Hotel-Dieu Hospital, AP-HP, Paris, France
- ECEVE UMR 1123, Inserm & Paris Cité University, Paris, France
| | - Martin Duracinsky
- URC ECO, Hotel-Dieu Hospital, AP-HP, Paris, France
- ECEVE UMR 1123, Inserm & Paris Cité University, Paris, France
| |
Collapse
|
3
|
Medioni J, Scimeca D, Marquez YL, Leray E, Dalichampt M, Hoertel N, Bennani M, Trempat P, Boujedaini N. Benefits of Homeopathic Complementary Treatment in Patients With Breast Cancer: A Retrospective Cohort Study Based on the French Nationwide Healthcare Database. Clin Breast Cancer 2023; 23:60-70. [PMID: 36376237 DOI: 10.1016/j.clbc.2022.10.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Revised: 09/21/2022] [Accepted: 10/01/2022] [Indexed: 12/27/2022]
Abstract
BACKGROUND Complementary therapy in oncology aims to help patients better cope with the illness and side effects (SEs) of cancer treatments that affect their quality of life (QOL). This study aimed to assess the benefits of homeopathic treatment on the health-related QOL (HRQOL) of patients with non-metastatic breast cancer (BC) prescribed in postsurgical complementary therapy. PATIENTS AND METHODS An extraction from the French nationwide healthcare database targeted all patients who underwent mastectomy for newly diagnosed BC between 2012 and 2013. HRQOL was proxied by the quantity of medication used to palliate the SEs of cancer treatments. RESULTS A total of 98,009 patients were included (mean age: 61 ± 13 years). Homeopathy was used in 11%, 26%, and 22% of patients respectively during the 7 to 12 months before surgery, the 6 months before, and 6 months after. Thereafter, the use remained stable at 15% for 4 years. Six months after surgery, there was a significant overall decrease (RR = 0.88, confidence interval (CI)95 = 0.87-0.89) in the dispensing of medication associated with SEs in patients treated with ≥ 3 dispensing of homeopathy compared to none. The decrease appeared to be greater for immunostimulants (RR = 0.79, (CI)95 = 0.74-0.84), corticosteroids (RR = 0.82, (CI)95 = 0.79-0.85), and antidiarrheals (RR = 0.83, (CI)95 = 0.77-0.88). CONCLUSION The study showed an increasing use of homeopathy in patients with BC following diagnosis. This use was maintained after surgery and seemed to play a role in helping patients to better tolerate the SEs of cancer treatments.
Collapse
Affiliation(s)
- Jacques Medioni
- APHP Hôpital Européen Georges Pompidou, Paris, France; Université Paris Cité, Paris, France
| | | | | | - Emmanuelle Leray
- Univ Rennes, EHESP, CNRS, Inserm, ARENES UMR 6051, RSMS U 1309, F-35000 Rennes, France
| | | | - Nicolas Hoertel
- Université Paris Cité, Paris, France; APHP Corentin Celton, Paris, France
| | | | | | | |
Collapse
|
4
|
Mastroianni B, Lochmann M, Girodet M, Blay JY, Christophe V, Chvetzoff G. L’oncologie intégrative : état des lieux et place d’une consultation dédiée dans un centre de lutte contre le cancer. Bull Cancer 2022; 109:1308-1314. [DOI: 10.1016/j.bulcan.2022.09.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 09/06/2022] [Accepted: 09/19/2022] [Indexed: 11/07/2022]
|
5
|
Homeopathy effects in patients during oncological treatment: a systematic review. J Cancer Res Clin Oncol 2022; 149:1785-1810. [PMID: 35731274 PMCID: PMC10097733 DOI: 10.1007/s00432-022-04054-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Accepted: 05/02/2022] [Indexed: 10/17/2022]
Abstract
PURPOSE In this systematic review we included clinical studies from 1800 until 2020 to evaluate evidence of the effectiveness of homeopathy on physical and mental conditions in patients during oncological treatment. METHOD In February 2021 a systematic search was conducted searching five electronic databases (Embase, Cochrane, PsychInfo, CINAHL and Medline) to find studies concerning use, effectiveness and potential harm of homeopathy in cancer patients. RESULTS From all 1352 search results, 18 studies with 2016 patients were included in this SR. The patients treated with homeopathy were mainly diagnosed with breast cancer. The therapy concepts include single and combination homeopathic remedies (used systemically or as mouth rinses) of various dilutions. Outcomes assessed were the influence on toxicity of cancer treatment (mostly hot flashes and menopausal symptoms), time to drain removal in breast cancer patients after mastectomy, survival, quality of life, global health and subjective well-being, anxiety and depression as well as safety and tolerance. The included studies reported heterogeneous results: some studies described significant differences in quality of life or toxicity of cancer treatment favouring homeopathy, whereas others did not find an effect or reported significant differences to the disadvantage of homeopathy or side effects caused by homeopathy. The majority of the studies have a low methodological quality. CONCLUSIONS For homeopathy, there is neither a scientifically based hypothesis of its mode of action nor conclusive evidence from clinical studies in cancer care.
Collapse
|
6
|
Sharma P, Sharma B, Aggarwal T, Kalita M. Homoeopathic Treatment as an Add-On for Minimizing After Effects of Conventionally Treated Cancer Patients: A Simple Randomized Pilot Study—Protocol from Northeast India Perspective. ASIAN JOURNAL OF ONCOLOGY 2021. [DOI: 10.1055/s-0041-1730099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
AbstractThe north-eastern region of India accounts for a total of 37,448 cancer cases reported from 11 population-based cancer registries (PBCRs) from 2012 to 2014. Studies suggest that with the holistic approach adopted by homoeopathy, not only the symptoms like cancer pain are alleviated, but also the overall well-being of the patient. Homoeopathy can be beneficial to minimize the treatment-induced adverse effects like radiation-induced mucositis, skin reactions, postoperative seroma, bleeding, and complications associated with the use of surgery, chemotherapy, and radiation therapy. This study intends to provide homoeopathic services as an add-on to conventional treatment to the patients referred for homoeopathic treatment after their due consent. The primary objective is to study the usefulness of homoeopathic medicines for combating the suffering of cancer patients having complaints other than cancer. A sample size of 70 patients per group in two arms (Arm A: standard allopathic drug and Arm B: standard allopathic drug + homoeopathic treatment) will be recruited using simple random sampling without repetition. Cancer patients reporting complaints other than cancer itself and suffering from the after-effects of cancer treatment with chemotherapy and radiation therapy to any reputed cancer institute will be screened and will be recruited according to inclusion and exclusion criteria. After completion of the six months study duration, results will be able to predict the role of homoeopathic treatment as an add-on to conventionally treated cancer patients to minimize the suffering other than cancer and the after-effects of chemotherapy and radiation therapy. If found significant, this could prove to be a contribution in the health care system in handling cancer cases that are very difficult to treat. Further, the cost-effectiveness of homoeopathy will enable developing countries to manage such a disease effectively.
Collapse
Affiliation(s)
- Pawan Sharma
- Clinical Research Unit for Homoeopathy (under Central Council for Research in Homeopathy, Ministry of AYUSH, Government of India), Aizawl, Mizoram, India
| | - Bindu Sharma
- Central Council for Research in Homoeopathy, Ministry of AYUSH, Government of India, New Delhi, India
| | - Tanya Aggarwal
- Central Council of Homoeopathy (under Ministry of AYUSH, Government of India), New Delhi, India
| | - Manoj Kalita
- Population Based Cancer Registry-Guwahati, National Cancer Registry Programme, National Centre for Disease Informatics and Research, Indian Council of Medical Research, Dr. B Borooah Cancer Institute, Guwahati, Assam, India
| |
Collapse
|
7
|
Jovenin N, Eche-Gass A, Chèze S, Launay-Vacher V, Mayeur D, Rey JB, Joly F, Krakowski I, Scotté F. Nausées-vomissements induits par les traitements anti-cancéreux (NVITAC) : quelle prise en charge en 2018 ? Mise à jour du référentiel AFSOS. Bull Cancer 2019; 106:497-509. [DOI: 10.1016/j.bulcan.2019.02.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Revised: 01/22/2019] [Accepted: 02/13/2019] [Indexed: 11/29/2022]
|
8
|
Chvetzoff G, Berthier A, Blanc E, Bourne Branchu V, Millaret A, Cropet C, Pérol D. [Osteopathy for chronic pain after breast cancer surgery: A monocentric randomised study]. Bull Cancer 2019; 106:436-446. [PMID: 31005246 DOI: 10.1016/j.bulcan.2019.03.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Revised: 01/24/2019] [Accepted: 03/04/2019] [Indexed: 11/18/2022]
Abstract
Twenty-five to 65% of patients suffer from chronic pain after breast cancer. The treatment combines analgesic drugs and psychophysical techniques. HYPOTHESIS Osteopathy improves the control of pain and the quality of life of patients. METHODS This randomized prospective single center study allocated patients to the initiation of a standard analgesic treatment exclusively (arm A) or associated to osteopathy (arm B) between from 1 to 12months after surgery. MAIN OBJECTIVE Intensity of pain (VAS at three months [j90]). SECONDARY OBJECTIVES Pain (VAS) at 6 and 12 months, analgesic consumption, anxiety/depression (HADS), and Quality of life (QLQ-C30). Eighty patients were planned to observe a 2-point difference in VAS (5% bilateral alpha, 90% power). RESULTS Twenty-eight patients (A: 14; B: 14, median age 50 years) were included from April 2011 to February 2014; the study was stopped due to a too slow recruitment. No difference in the VAS pain score between arms was observed at j90 (P=0.258), nor at 6 and 12 months. At j90, the HADS depression score was reduced in arm B (P=0.049). Improvement in the overall score of quality of life (P=0.015), and reduced pain sub-score (P=0.021) were observed at j90 in arm B. DISCUSSION Patients are strongly seeking complementary therapies. Few studies exist. Our study has encountered major recruitment difficulties therefore limiting the interpretation of the results. Despite the absence of difference in the main objective, some other scores (QOL, depression) are noteworthy in favor of osteopathy. Further multicentric studies are needed.
Collapse
Affiliation(s)
- Gisèle Chvetzoff
- Centre Léon-Bérard, département de soins de support, 28, rue Laennec, 69373 Lyon, France.
| | - Audrey Berthier
- Centre Léon-Bérard, département de soins de support, 28, rue Laennec, 69373 Lyon, France
| | - Ellen Blanc
- Centre Léon-Bérard, direction de la recherche clinique et de l'innovation, 28, rue Laennec, 69373 Lyon, France
| | - Valérie Bourne Branchu
- Centre Léon-Bérard, direction de la recherche clinique et de l'innovation, 28, rue Laennec, 69373 Lyon, France
| | - Anne Millaret
- Centre Léon-Bérard, direction de la recherche clinique et de l'innovation, 28, rue Laennec, 69373 Lyon, France
| | - Claire Cropet
- Centre Léon-Bérard, direction de la recherche clinique et de l'innovation, 28, rue Laennec, 69373 Lyon, France
| | - David Pérol
- Centre Léon-Bérard, direction de la recherche clinique et de l'innovation, 28, rue Laennec, 69373 Lyon, France
| |
Collapse
|
9
|
Does a homeopathic medicine reduce hot flushes induced by adjuvant endocrine therapy in localized breast cancer patients? A multicenter randomized placebo-controlled phase III trial. Support Care Cancer 2018; 27:1879-1889. [DOI: 10.1007/s00520-018-4449-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Accepted: 08/30/2018] [Indexed: 10/28/2022]
|
10
|
de Nonneville A, Gonçalves A. Réponse à la lettre d’A. Braillon et F. Taiebi. Bull Cancer 2018; 105:641-642. [DOI: 10.1016/j.bulcan.2018.06.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2018] [Accepted: 05/19/2018] [Indexed: 10/28/2022]
|
11
|
Homéopathie et cancer, quelles sont les preuves ? Bull Cancer 2018; 105:426-430. [DOI: 10.1016/j.bulcan.2017.12.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2017] [Revised: 12/04/2017] [Accepted: 12/07/2017] [Indexed: 11/18/2022]
|
12
|
Bagot JL, Karp JC, Messerschmitt C, Lavallée V, Blajman H, Veron F, Fischer-Levy I, Tourneur-Bagot O, Wagner JP. Therapeutic recommendations of the International Homeopathic Society of Supportive Care in Oncology (IHSSCO). ACTA ACUST UNITED AC 2017. [DOI: 10.1016/j.revhom.2017.10.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
13
|
|
14
|
Greenlee H, DuPont-Reyes MJ, Balneaves LG, Carlson LE, Cohen MR, Deng G, Johnson JA, Mumber M, Seely D, Zick SM, Boyce LM, Tripathy D. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin 2017; 67:194-232. [PMID: 28436999 PMCID: PMC5892208 DOI: 10.3322/caac.21397] [Citation(s) in RCA: 381] [Impact Index Per Article: 54.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Answer questions and earn CME/CNE Patients with breast cancer commonly use complementary and integrative therapies as supportive care during cancer treatment and to manage treatment-related side effects. However, evidence supporting the use of such therapies in the oncology setting is limited. This report provides updated clinical practice guidelines from the Society for Integrative Oncology on the use of integrative therapies for specific clinical indications during and after breast cancer treatment, including anxiety/stress, depression/mood disorders, fatigue, quality of life/physical functioning, chemotherapy-induced nausea and vomiting, lymphedema, chemotherapy-induced peripheral neuropathy, pain, and sleep disturbance. Clinical practice guidelines are based on a systematic literature review from 1990 through 2015. Music therapy, meditation, stress management, and yoga are recommended for anxiety/stress reduction. Meditation, relaxation, yoga, massage, and music therapy are recommended for depression/mood disorders. Meditation and yoga are recommended to improve quality of life. Acupressure and acupuncture are recommended for reducing chemotherapy-induced nausea and vomiting. Acetyl-L-carnitine is not recommended to prevent chemotherapy-induced peripheral neuropathy due to a possibility of harm. No strong evidence supports the use of ingested dietary supplements to manage breast cancer treatment-related side effects. In summary, there is a growing body of evidence supporting the use of integrative therapies, especially mind-body therapies, as effective supportive care strategies during breast cancer treatment. Many integrative practices, however, remain understudied, with insufficient evidence to be definitively recommended or avoided. CA Cancer J Clin 2017;67:194-232. © 2017 American Cancer Society.
Collapse
Affiliation(s)
- Heather Greenlee
- Assistant Professor, Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY
- Member, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY
| | - Melissa J DuPont-Reyes
- Doctoral Fellow, Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY
| | - Lynda G Balneaves
- Associate Professor, College of Nursing, Rady Faculty of Health Sciences, Winnipeg, MB, Canada
| | - Linda E Carlson
- Professor, Department of Oncology, University of Calgary, Calgary, AB, Canada
| | - Misha R Cohen
- Adjunct Professor, American College of Traditional Chinese Medicine at California Institute of Integral Studies, San Francisco, CA
- Clinic Director, Chicken Soup Chinese Medicine, San Francisco, CA
| | - Gary Deng
- Medical Director, Integrative Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Jillian A Johnson
- Post-Doctoral Scholar, Department of Biobehavioral Health, The Pennsylvania State University, University Park, PA
| | | | - Dugald Seely
- Executive Director, Ottawa Integrative Cancer Center, Ottawa, ON, Canada
- Executive Director of Research, Canadian College of Naturopathic Medicine, Toronto, ON, Canada
| | - Suzanna M Zick
- Research Associate Professor, Department of Family Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI
- Research Associate Professor, Department of Nutritional Sciences, School of Public Health, University of Michigan, Ann Arbor, MI
| | - Lindsay M Boyce
- Research Informationist, Memorial Sloan Kettering Library, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Debu Tripathy
- Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
15
|
Thomas ET, Clark J, Glasziou P. Publication and outcome reporting of homeopathy trials registered in ClinicalTrials.gov. ACTA ACUST UNITED AC 2017. [DOI: 10.1111/fct.12278] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Elizabeth T Thomas
- Faculty of Health Sciences and Medicine; Bond University; 14 University Drive Robina QLD 4226 Australia
| | - Justin Clark
- Faculty of Health Sciences and Medicine; Centre for Research in Evidence-Based Practice; Bond University; 14 University Drive Robina QLD 4226 Australia
| | - Paul Glasziou
- Faculty of Health Sciences and Medicine; Centre for Research in Evidence-Based Practice; Bond University; 14 University Drive Robina QLD 4226 Australia
| |
Collapse
|
16
|
Chinese Herbal Medicine as Adjunctive Therapy to Chemotherapy for Breast Cancer: A Systematic Review and Meta-Analysis. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2016; 2016:3281968. [PMID: 27190531 PMCID: PMC4842043 DOI: 10.1155/2016/3281968] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Revised: 02/06/2016] [Accepted: 03/01/2016] [Indexed: 11/17/2022]
Abstract
Chinese herbal medicine (CHM) has been increasingly employed during therapy for breast cancer, but its efficacy remains a matter of debate. This systematic review examined randomized controlled trials to provide a critical evaluation of this treatment. The results demonstrated that the combined use of CHM with chemotherapy may improve the immediate tumor response and reduce chemotherapy-associated adverse events. Our findings highlight the poor quality of Chinese studies, and additional well-designed randomized controlled trials addressing the role of CHM are warranted. The lack of molecular-based evidence for CHM and Zheng has resulted in a limited understanding and acceptance of CHM and traditional Chinese medicine in Western countries. We believe that researchers should immediately explore a CHM-based cure, and CHM should be applied to routine care as soon as conclusive data are available.
Collapse
|
17
|
Ernst E. [Not Available]. MMW Fortschr Med 2013; 155:33. [PMID: 23930413 DOI: 10.1007/s15006-013-0873-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
|